Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters.

ABSTRACT: Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs).¹ Recently approved vaccines provide needed interventions, albeit at prices that may limit their global access.² Subunit vaccines based on recombinant proteins are suited for large-volume microbial manufacturing to yield billions of doses annually, minimizing their manufacturing costs.³ These types of vaccines are well-established, proven interventions with multiple safe and efficacious commercial examples.^4-6 Many vaccine candidates of this type for SARS-CoV-2 rely on sequences containing the receptor-binding domain (RBD), which mediates viral entry to cells via ACE2.^7,8 Here we report an engineered sequence va

SUBMITTER: Dalvie NC 

PROVIDER: S-EPMC7941618 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature